Granted Patent
B2
US 12,515,069 · App. 17/217,789 · Granted Jan 6, 2026
Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
Assignee:
Massachusetts Institute of Technology
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Devices, systems, and methods for treating dementia or Alzheimer's disease in a subject in need thereof. In one example, chronic visual stimuli having a frequency of about 30 Hz to about 50 Hz, and more specifically about 40 Hz, are non-invasively delivered to the subject to entrain gamma oscillations in multiple brain regions of the subject, including the prefrontal cortex (PFC) and the hippocampus. The entrained gamma oscillations modulate neuronal activity across multiple brain regions (e.g., facilitate functional binding of neural networks at low gamma frequencies) to induce various neuroprotective effects (e.g., amelioration of amyloid plaques and tau hyper-phosphorylation) and reduce neurodegeneration. Neuronal activity mediated by the chronic visual stimuli reduces an immune response in microglia and ameliorates aberrantly modified genes and proteins involved in membrane trafficking, intracellular transport, synaptic function, neuroinflammation and DNA damage response. Behavior modification including enhanced learning and memory is observed.
Claims (21)
1 . A method for increasing expression of genes and/or proteins associated with vesicle mediated transport in neurons in a subject for treating dementia or Alzheimer's disease in the subject in need thereof, the method comprising:
non-invasively delivering visual stimuli having a frequency of about 30 Hz to about 50 Hz to the subject for at least 6 weeks, such that the intensity of the visual stimuli received by the subject is from 300 lux to 1500 lux and wherein the visual stimuli increases an expression of genes and/or proteins associated with vesicle mediated transport in neurons in the subject.
2 . The method of claim 1 , wherein the visual stimuli have a frequency of about 40 Hz.
3 . The method of claim 1 , wherein the non-invasively delivering further includes non-invasively delivering the visual stimuli to the subject for at least 1 hour per day.
4 . The method of claim 1 , wherein the non-invasively delivering further includes increasing expression of one or more genes selected from the group consisting of: vGlut1, Slcl a3, Chmp2a, Ank1, Tmed10, Apoe, Clu, and Myo6.
5 . The method of claim 1 , wherein the non-invasively delivering further includes increasing synaptic transmission and/or synaptic plasticity in the neurons of the subject.
6 . The method of claim 1 , wherein the non-invasively delivering further includes increasing expression of genes and/or proteins associated with synaptic transmission in the neurons of the subject.
7 . The method of claim 6 , wherein the increasing expression of genes and/or proteins associated with synaptic transmission further includes increasing expression of one or more genes or proteins selected from the group consisting of: Syngap1, Synaptophysin, Grin1, Grin2b, Gabbr2, Snap25, Shank1, Shank2, Shank3, Dlgap 1, and Dlgap3.
8 . The method of claim 1 , wherein the non-invasively delivering further includes reducing phosphorylation of dynamin in the neurons of the subject.
9 . The method of claim 1 , wherein the non-invasively delivering further includes concurrently entraining synchronized gamma oscillations in multiple brain regions of the subject including at least the prefrontal cortex and the hippocampus of the subject.
10 . The method of claim 9 , wherein the multiple brain regions of the subject further include the visual cortex and the somatosensory cortex of the subject.
11 . The method of claim 1 , further comprising controlling a light-emitting device to generate the visual stimuli.
12 . A method for modifying vesicle mediated transport in neurons in a subject for treating dementia or Alzheimer's disease in the subject in need thereof, the method comprising:
non-invasively delivering visual stimuli having a frequency of about 30 Hz to about 50 Hz to the subject for at least 6 weeks, such that the intensity of the visual stimuli received by the subject is from 300 lux to 1500 lux and wherein the visual stimuli modifies vesicle mediated transport in neurons in the subject.
13 . The method of claim 12 , wherein the visual stimuli have a frequency of about 40 Hz.
14 . The method of claim 12 , wherein the non-invasively delivering further includes non-invasively delivering the visual stimuli to the subject for at least 1 hour per day.
15 . The method of claim 12 , wherein the non-invasively delivering further includes increasing synaptic transmission in the neurons of the subject.
16 . The method of claim 12 , wherein the non-invasively delivering further includes reducing phosphorylation of dynamin in the neurons of the subject.
17 . The method of claim 12 , wherein the non-invasively delivering further includes concurrently entraining synchronized gamma oscillations in multiple brain regions of the subject including at least the prefrontal cortex and the hippocampus of the subject.
18 . The method of claim 17 , wherein the multiple brain regions of the subject further include the visual cortex and the somatosensory cortex of the subject.
19 . The method of claim 12 , further comprising controlling a light-emitting device to generate the visual stimuli.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Jan 17, 2024
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066340/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 30, 2021
From: ADAIKKAN, CHINNAKKARUPPAN; TSAI, LI-HUEI
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 056100/0947 →
Continuity (5)
Provisional Application
62570929
· Oct 11, 2017
Provisional Application
62570250
· Oct 10, 2017
References Cited (400)
US 4315502A
· Gorges
· 1982
[cited by applicant]
US 4449047A
· Monroe
· 1984
[cited by applicant]
US 4456910A
· DiMassimo et al.
· 1984
[cited by applicant]
US 4674852A
· Tanaka
· 1987
[cited by applicant]
US 5151687A
· Younger
· 1992
[cited by applicant]
US 5534953A
· Schmielau
· 1996
[cited by applicant]
US 5659287A
· Donati et al.
· 1997
[cited by applicant]
US 5923398A
· Goldman
· 1999
[cited by applicant]
US 5934967A
· Brown et al.
· 1999
[cited by applicant]
US 6066163A
· John
· 2000
[cited by applicant]
US 6071229A
· Rubins
· 2000
[cited by applicant]
US 6113537A
· Castano
· 2000
[cited by applicant]
US 6167298A
· Levin
· 2000
[cited by applicant]
US 6206537B1
· Hauck
· 2001
[cited by applicant]
US 6234953B1
· Thomas et al.
· 2001
[cited by applicant]
US 6443977B1
· Jaillet
· 2002
[cited by applicant]
US 6463328B1
· John
· 2002
[cited by applicant]
US 6539263B1
· Schiff et al.
· 2003
[cited by applicant]
US 6733490B1
· Falsini et al.
· 2004
[cited by applicant]
US 7010356B2
· Jog et al.
· 2006
[cited by applicant]
US 7361074B1
· Periman et al.
· 2008
[cited by applicant]
US 7446785B1
· Hewlett et al.
· 2008
[cited by applicant]
US 7569545B2
· Li et al.
· 2009
[cited by applicant]
US 7645226B2
· Shealy et al.
· 2010
[cited by applicant]
US 7715910B2
· Hargrove et al.
· 2010
[cited by applicant]
US 7748846B2
· Todd
· 2010
[cited by applicant]
US 7769439B2
· Vesely et al.
· 2010
[cited by applicant]
US 7798982B2
· Zets et al.
· 2010
[cited by applicant]
US 8070669B2
· Brunelle et al.
· 2011
[cited by applicant]
US 8083392B2
· Chien
· 2011
[cited by applicant]
US 8121694B2
· Molnar et al.
· 2012
[cited by applicant]
US 8239030B1
· Hagedorn et al.
· 2012
[cited by applicant]
US 8267851B1
· Kroll
· 2012
[cited by applicant]
US 8280502B2
· Hargrove et al.
· 2012
[cited by applicant]
US 8328420B2
· Abreu
· 2012
[cited by applicant]
US 8380314B2
· Panken et al.
· 2013
[cited by applicant]
US 8396545B2
· Berridge et al.
· 2013
[cited by applicant]
US 8423144B2
· Tass et al.
· 2013
[cited by applicant]
US 8543219B2
· Tass
· 2013
[cited by applicant]
US 8577470B2
· Assaf et al.
· 2013
[cited by applicant]
US 8579793B1
· Honeycutt et al.
· 2013
[cited by applicant]
US 8591392B2
· Baror et al.
· 2013
[cited by applicant]
US 8636640B2
· Chang
· 2014
[cited by applicant]
US 8700167B2
· Sabel
· 2014
[cited by applicant]
US 8845704B2
· Dunning
· 2014
[cited by examiner]
US 8892207B2
· Nelson et al.
· 2014
[cited by applicant]
US 8894696B2
· Hurst
· 2014
[cited by applicant]
US 8914119B2
· Wu et al.
· 2014
[cited by applicant]
US 8932218B1
· Thompson
· 2015
[cited by applicant]
US 8942809B2
· Assaf et al.
· 2015
[cited by applicant]
US 9119583B2
· Tass
· 2015
[cited by applicant]
US 9272118B1
· Acton
· 2016
[cited by applicant]
US 9302069B2
· Tass et al.
· 2016
[cited by applicant]
US 9629976B1
· Acton
· 2017
[cited by applicant]
US 20010027278A1
· Kaufman et al.
· 2001
[cited by applicant]
US 20010039012A1
· Lapidus
· 2001
[cited by applicant]
US 20050070977A1
· Molina
· 2005
[cited by applicant]
US 20070038142A1
· Todd et al.
· 2007
[cited by applicant]
US 20070191727A1
· Fadem
· 2007
[cited by applicant]
US 20070225773A1
· Shen et al.
· 2007
[cited by applicant]
US 20070253561A1
· Williams et al.
· 2007
[cited by applicant]
US 20080181882A1
· Hahn
· 2008
[cited by applicant]
US 20080249439A1
· Tracey et al.
· 2008
[cited by applicant]
US 20080255949A1
· Genco et al.
· 2008
[cited by applicant]
US 20090005837A1
· Olmstead
· 2009
[cited by applicant]
US 20090093403A1
· Zhang et al.
· 2009
[cited by applicant]
US 20090270776A1
· Chang
· 2009
[cited by applicant]
US 20090306555A1
· Goto
· 2009
[cited by applicant]
US 20100190129A1
· Paz
· 2010
[cited by applicant]
US 20100217358A1
· Hebert et al.
· 2010
[cited by applicant]
US 20100274329A1
· Bradley et al.
· 2010
[cited by applicant]
US 20120065709A1
· Dunning et al.
· 2012
[cited by applicant]
US 20120253236A1
· Snow et al.
· 2012
[cited by applicant]
US 20120289869A1
· Tyler
· 2012
[cited by applicant]
US 20130021138A1
· Ezzat et al.
· 2013
[cited by applicant]
US 20130211238A1
· deCharms
· 2013
[cited by applicant]
US 20130211277A1
· Berg et al.
· 2013
[cited by applicant]
US 20130338738A1
· Garcia Molina
· 2013
[cited by examiner]
US 20140085446A1
· Hicks
· 2014
[cited by applicant]
US 20140303025A1
· Keuren-Jensen et al.
· 2014
[cited by applicant]
US 20140303424A1
· Glass
· 2014
[cited by applicant]
US 20140316192A1
· Zambotti et al.
· 2014
[cited by applicant]
US 20140324138A1
· Wentz et al.
· 2014
[cited by applicant]
US 20140336514A1
· Peyman
· 2014
[cited by applicant]
US 20150002025A1
· Maricic et al.
· 2015
[cited by applicant]
US 20150157604A1
· Morozova et al.
· 2015
[cited by applicant]
US 20150337030A1
· Abeliovich
· 2015
[cited by applicant]
US 20160051793A1
· Gibson-Horn
· 2016
[cited by applicant]
US 20160067087A1
· Tedford et al.
· 2016
[cited by applicant]
US 20160091758A1
· Yoneyama
· 2016
[cited by applicant]
US 20160235980A1
· Berman et al.
· 2016
[cited by applicant]
US 20170143966A1
· Reymers et al.
· 2017
[cited by applicant]
US 20170224949A1
· Acton
· 2017
[cited by applicant]
US 20180206737A1
· Colman
· 2018
[cited by applicant]
US 20190030190A1
· Peyman
· 2019
[cited by applicant]
US 20190076670A1
· Vyshedskiy
· 2019
[cited by applicant]
US 20190126056A1
· Bogdan
· 2019
[cited by applicant]
US 20190254775A1
· Gregg et al.
· 2019
[cited by applicant]
US 20190388020A1
· Stauch et al.
· 2019
[cited by applicant]
US 20200171267A1
· Millard
· 2020
[cited by examiner]
US 20210030998A1
· Wong
· 2021
[cited by applicant]
US 20210236837A1
· Lu
· 2021
[cited by applicant]
US 20210339043A1
· Malchano et al.
· 2021
[cited by applicant]
US 20220008746A1
· Malchano et al.
· 2022
[cited by applicant]
US 20220151864A1
· Tsai et al.
· 2022
[cited by applicant]
US 20230166072A1
· Malchano et al.
· 2023
[cited by applicant]
US 20230173295A1
· Kim et al.
· 2023
[cited by applicant]
US 20230181905A1
· Tsai et al.
· 2023
[cited by applicant]
US 20240293680A1
· Malchano et al.
· 2024
[cited by applicant]
US 20240325780A1
· Malchano et al.
· 2024
[cited by applicant]
AU 2017363200A1
· 2019
[cited by applicant]
AU 2018347870A1
· 2020
[cited by applicant]
CA 2979686A1
· 2016
[cited by applicant]
CA 2979687A1
· 2016
[cited by applicant]
CA 3078704A1
· 2019
[cited by applicant]
CN 1662277A
· 2005
[cited by applicant]
CN 1991364A
· 2007
[cited by applicant]
CN 102791332A
· 2012
[cited by applicant]
CN 103298480A
· 2013
[cited by applicant]
CN 103492564A
· 2014
[cited by applicant]
CN 104039353A
· 2014
[cited by applicant]
CN 104783788A
· 2015
[cited by applicant]
CN 103932701B
· 2015
[cited by applicant]
CN 105278387A
· 2016
[cited by applicant]
CN 106103711A
· 2016
[cited by applicant]
CN 107002076A
· 2017
[cited by applicant]
CN 108725462A
· 2018
[cited by applicant]
CN 111655319A
· 2020
[cited by applicant]
EP 0911398A3
· 1999
[cited by applicant]
EP 1642609A1
· 2006
[cited by examiner]
EP 2075035A1
· 2009
[cited by applicant]
EP 2489402A2
· 2012
[cited by applicant]
EP 3694464A4
· 2020
[cited by applicant]
EP 3694593A1
· 2020
[cited by applicant]
EP 3541467B1
· 2024
[cited by applicant]
IT RM20090027A1
· 2010
[cited by applicant]
JP H08150210A
· 1996
[cited by applicant]
JP 2006525039A
· 2006
[cited by applicant]
JP 2008520280A
· 2008
[cited by applicant]
JP 2011514194A
· 2011
[cited by applicant]
JP 2014071825A
· 2014
[cited by applicant]
JP 2015519096A
· 2015
[cited by applicant]
JP 2018525754A
· 2018
[cited by applicant]
KR 1020020025884A
· 2002
[cited by applicant]
KR 1020130101596A
· 2013
[cited by applicant]
KR 1020140144272A
· 2014
[cited by applicant]
KR 20160129752A
· 2016
[cited by applicant]
WO 1997016196A1
· 1997
[cited by applicant]
WO 0184141A1
· 2001
[cited by applicant]
WO 2007062367A2
· 2007
[cited by applicant]
WO 2008041129A2
· 2008
[cited by applicant]
WO 2008101128A1
· 2008
[cited by applicant]
WO 2008147958A1
· 2008
[cited by applicant]
WO 2010123577A2
· 2010
[cited by applicant]
WO 2008041129A3
· 2011
[cited by applicant]
WO 2011042908A1
· 2011
[cited by applicant]
WO 2011057028A1
· 2011
[cited by applicant]
WO 2012024243A1
· 2012
[cited by applicant]
WO 2013061597A1
· 2013
[cited by applicant]
WO 2013152348A1
· 2013
[cited by applicant]
WO 2014040175A1
· 2014
[cited by applicant]
WO 2014107795A1
· 2014
[cited by applicant]
WO 2014130960A1
· 2014
[cited by applicant]
WO 2014162271A2
· 2014
[cited by applicant]
WO 2014179331A2
· 2014
[cited by applicant]
WO 2015034673A1
· 2015
[cited by applicant]
WO 2015066679A2
· 2015
[cited by applicant]
WO 2015069632A1
· 2015
[cited by applicant]
WO 2015149170A1
· 2015
[cited by applicant]
WO 2015066679A3
· 2015
[cited by applicant]
WO 2017091758A1
· 2017
[cited by applicant]
WO WO2017091698A1
· 2017
[cited by examiner]
WO 2017172728A1
· 2017
[cited by applicant]
WO 2018094226A1
· 2018
[cited by applicant]
WO 2019046338A1
· 2019
[cited by applicant]
WO 2019074637A1
· 2019
[cited by applicant]
WO 2019075094A1
· 2019
[cited by applicant]
WO 2019241430A2
· 2019
[cited by applicant]
WO 2020041502A1
· 2020
[cited by applicant]
WO 2021216957A1
· 2021
[cited by applicant]
WO 2021221879A1
· 2021
[cited by applicant]
WO 2022027030A1
· 2022
[cited by applicant]
WO 2022192277A1
· 2022
[cited by applicant]
Chinese Second Office Action with English Translation in Chinese Application No. 201880073535.8 dated May 25, 2022, 5 pages.
[cited by applicant]
Korean Office Action with English translation thereof in Korean Application No. 10-2020-7013291, dated Jun. 2, 2022, 11 pages.
[cited by applicant]
Mosabbir et al. “The effects of long-term 40-Hz physioacoustic vibrations on motor impairments in Parkinson's disease: a double-blinded randomized control trial.” Healthcare. vol. 8. No. 2. MDPI, 2020, 13 pages.
[cited by applicant]
Notice of Allowance (with Search Report) with English Translation dated May 17, 2022 in Chinese Application No. 201680075447.2 8 pages.
[cited by applicant]
Poza et al. “Analysis of spontaneous MEG activity in patients with Alzheimer's disease using spectral entropies.” 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, …
[cited by applicant]
Third Office Action in CA Application No. 3003183, dated Jun. 20, 2022, 4 pages.
[cited by applicant]
Chinese Office Action and English Translation Thereof in Chinese Patent Application No. 201680075447.2 dated Jun. 1, 2021, 31 pages.
[cited by applicant]
Sauer et al., “Impaired fast-spiking interneuron function in a genetic mouse model of depression.” Elife 4 (2015): e04979. 20 pages.
[cited by applicant]
Wang et al., “The gamma frequency band neural oscillation: generation mechanisms and functions.” Progress in Biochemistry and Biophysics 38.8 (2011): 688-693.
[cited by applicant]
Japanese Office Action and English Translation thereof in Japanese App. No. 2020-520207 dated May 9, 2022 13 pages.
[cited by applicant]
Briones et al., “Dysregulation in myelination mediated by persistent neuroinflammation: possible mechanisms in chemotherapy-related cognitive impairment.” Brain, behavior, and immunity 35 (2014): 23-32.
[cited by applicant]
Correa et al., “A prospective evaluation of changes in brain structure and cognitive functions in adult stem cell transplant recipients.” Brain imaging and behavior 7.4 (2013): 478-490.
[cited by applicant]
Gibson et al., “Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain.” Science 344.6183 (2014). 27 pages.
[cited by applicant]
International Search Report and Written Opinion in International Patent Application No. PCT/US2021/028776 dated Aug. 13, 2021, 19 pages.
[cited by applicant]
Jiang et al., “PAN-811 prevents chemotherapy-induced cognitive impairment and preserves neurogenesis in the hippocampus of adult rats.” Plos one 13.1 (2018): e0191866.
[cited by applicant]
Krynetskiy et al., “Establishing a model for assessing DNA damage in murine brain cells as a molecular marker of chemotherapy-associated cognitive impairment.” Life sciences 93.17 (2013): 605-610.
[cited by applicant]
Kumburovic et al., “Antioxidant effects of Satureja hortensis L. attenuate the anxiogenic effect of cisplatin in rats.” Oxidative medicine and cellular longevity 2019 (2019). 15 pages.
[cited by applicant]
Palpagama et al., “The role of microglia and astrocytes in Huntington's disease.” Frontiers in molecular neuroscience 12 (2019): 258. 15 pages.
[cited by applicant]
“40hz Light Therapy addressing Alzheimer's news!” Indiegogo https://www.indiegogo.com/projects/40hz-light-therapy-addressing-alzheimer-s-news#/, https://www.indiegogo.com, Internet Archive Wayback Machine earliest Inter…
[cited by applicant]
“Brainsway: Deep TMS Therapy,” Brainsway (2014): http://www.brainsway.com/us.
[cited by applicant]
“Good Vibrations Can Help Alzheimer's Patients,” Awakening from Alzheimer's http://www.awakeningfromalzheimers.com/good-vibrations-can-help-alzheimers-patients/, Internet Archive Wayback Machine earliest Internet archiv…
[cited by applicant]
“PSIO Manual,” PSIO http://www.psioplanet.com/download/manuals/manuel-psio-1.1-EN.pdf, http://www.psoplanet.com/, Internet Archive Wayback Machine earliest Internet archived date Mar. 2, 2013, 16 pages.
[cited by applicant]
Adaikkan et al., “Gamma entrainment binds higher-order brain regions and offers neuroprotection.” Neuron 102.5 (2019): 929-943.
[cited by applicant]
Alzheimer's Life Therapy App. Apple Store. Current version 1.5.7 released Aug. 6, 2019, earliest version 1.0.3 released Jan. 17, 2018. Accessed at https://apps.apple.com/us/app/alzheimers-light-therapy/id1327175926. 3 p…
[cited by applicant]
Aronov, D. et al., “Engagement of neural circuits underlying 2D spatial navigation in a rodent virtual reality system,” Neuron, vol. 84 (Oct. 2014): 442-456.
[cited by applicant]
Barton, A. “Sound vibration treatment may boost brain activity in Alzheimer's patients,” The Globe and Mail (2016): http://www.theglobeandmail.com/life/health-and-fitness/health/sound-vibration-treatment-may-boost-brain…
[cited by applicant]
Bartos, M. et al., “Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks,” Nature Reviews Neuroscience, vol. 8 (Jan. 2007): 45-56.
[cited by applicant]
Basar, E. et al., “Delay of cognitive gamma responses in Alzheimer's disease,” NeuroImage: Clinical, vol. 11 (2016): 106-115.
[cited by applicant]
Bebop. Mace Virtual Labs. Accessed at https://www.macevl.com/bebop on Nov. 18, 2020. 4 pages.
[cited by applicant]
Berman et al., “Photoblomodulation with near infrared light helmet in a pilot, placebo controlled clinical trial in dementia patients testing memory and cognition.” Journal of neurology and neuroscience 8.1 (2017). 15 p…
[cited by applicant]
Berman et al., Chapter 32—Noninvasive neurotherapeutic treatment of neurodegeneration: integrating photobiomodulation and neurofeedback training in Photobiomodulation in the Brain Low-Level Laser (Light) Therapy in Neur…
[cited by applicant]
Berman et al., Chapter 4—Photobiomodulation and Other Light Stimulation Procedures in Rhythmic Stimulation Procedures in Neuromodulation 2017, pp. 97-129.
[cited by applicant]
Bero, A. et al., “Neuronal activity regulates the regional vulnerability to amyloid-β deposition,” Nature Neuroscience, vol. 14 (May 2011): 750-756.
[cited by applicant]
Boissonneault, V. et al., “Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease,” Brain, vol. 132 (Apr. 2009): 1078-1092.
[cited by applicant]
Bragin, A. et al., “Gamma (40-100 Hz) oscillation in the hippocampus of the behaving rat,” Journal of Neuroscience, vol. 15 (Jan. 1995): 47-60.
[cited by applicant]
Busche, M. et al., “Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models,” Nature Neuroscience, vol. 18 (Dec. 2015): 1725-1727.
[cited by applicant]
Buzsaki et al., “Mechanisms of Gamma Oscillations,” Rev. Neurosci. 35, 203-23 (2012).
[cited by applicant]
Buzsaki, G. “Rhythms of the Brain,” Oxford University Press (2006).
[cited by applicant]
Buzsaki, G. “Theta oscillations in the hippocampus,” Neuron, vol. 33 (Jan. 2002): 325-340.
[cited by applicant]
Buzsaki, G. et al., “Hippocampal network patterns of activity in the mouse,” Neuroscience, vol. 116 (2003): 201-211.
[cited by applicant]
Buzsaki, G. et al., “Scaling brain size, keeping timing: evolutionary preservation of brain rhythms,” Neuron, vol. 80 (Oct. 2013): 751-764.
[cited by applicant]
Cardin, J. et al., “Driving fast-spiking cells induces gamma rhythm and controls sensory responses,” Nature, vol. 459 (Apr. 2009): 663-667.
[cited by applicant]
Carr, M. et al., “Hippocampal replay in the awake state: a potential substrate for memory consolidation and retrieval,” Nature Neuroscience, vol. 14 (Feb. 2011): 147-153.
[cited by applicant]
Carr, M. et al., “Transient slow gamma synchrony underlies hippocampal memory replay,” Neuron, vol. 75 (Aug. 2012): 700-713.
[cited by applicant]
Cataldo, A. et al., “Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations,” American Journal o…
[cited by applicant]
Chitu, V. et al., “Colony-stimulating factor-1 in immunity and inflammation,” Current Opinion in Immunology, vol. 18 (Feb. 2006): 39-48.
[cited by applicant]
Chiu et al., “Nasal administration of mesenchymal stem cells restores cisplatin-induced cognitive impairment and brain damage in mice.” Oncotarget 9.85 (2018): 35581. 17 pages.
[cited by applicant]
Chiu, I. et al., “A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model,” Cell Reports, vol. 4 (Jul. 2013): 385-401.
[cited by applicant]
Chung, K. et al., “Structural and molecular interrogation of intact biological systems,” Nature, vol. 497 (May 2013): 332-337.
[cited by applicant]
Cirrito, J. et al., “In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life,” The Journal of Neuroscience, vol. 23 (Oct. 2003): 8844-…
[cited by applicant]
Clements-Cortes et al., “Short-term effects of rhythmic sensory stimulation in Alzheimer's disease: An exploratory pilot study.” Journal of Alzheimer's Disease 52.2 (2016): 651-660.
[cited by applicant]
Clements-Cortes, A. “Sound Stimulation in Patients With Alzheimer's Disease,” Annals of Long-Term Care: Clinical Care and Aging, vol. 23 (May 2015): 10-16.
[cited by applicant]
Colgin, L. et al., “Frequency of gamma oscillations routes flow of information in the hippocampus,” Nature, vol. 462 (Nov. 2009): 353-357.
[cited by applicant]
Colgin, L. et al., “Gamma oscillations in the hippocampus,” Physiology, vol. 25 (Oct. 2010): 319-329.
[cited by applicant]
Cronk, J. et al., “Methyl-CpG binding protein 2 regulates microglia and macrophage gene expression in response to inflammatory stimuli,” Immunity, vol. 42 (Apr. 2015): 679-691.
[cited by applicant]
Crotti, A. et al., “Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors,” Nature Neuroscience , vol. 17 (Apr. 2014): 513-521.
[cited by applicant]
Das, U. et al., “Activity-induced convergence of App and Bace-1 in acidic microdomains via an endocytosis-dependent pathway,” Neuron, vol. 79 (Aug. 2013): 447-460.
[cited by applicant]
Eckhorn, R. et al., “Coherent Oscillations: a Mechanism of Feature Linking in the Visual Cortex,” Biological Cybernetics, vol. 60 (1988): 121-130.
[cited by applicant]
Erny, D. et al., “Host microbiota constantly control maturation and function of microglia in the CNS,” Nature Neuroscience, vol. 18 (Jun. 2015): 965-977.
[cited by applicant]
Extended European Search Report in European Patent Application No. 16869248.1 dated Jul. 15, 2019, 7 pages.
[cited by applicant]
Extended European Search Report in European Patent Application No. 18866506.1 dated Jun. 9, 2021, 8 pages.
[cited by applicant]
Extended European Search Report in European Patent Application No. 18866752.1 dated Jun. 22, 2021, 7 pages.
[cited by applicant]
Final Office Action dated Jun. 4, 2018 for U.S. Appl. No. 15/360,637, 11 pages.
[cited by applicant]
Fisher Wallace Stimulator http://www.fish vallace.com/, Internet Archive Wayback Machine earliest Internet archived date Jul. 13, 2017, 7 pages.
[cited by applicant]
Foster, D. et al., “Reverse replay of behavioural sequences in hippocampal place cells during the awake state,” Nature, vol. 440 (Mar. 2006):680-683.
[cited by applicant]
Fries, P. et al., “The gamma cycle,” Trends in Neurosciences, vol. 30 (Jul. 2007): 309-316.
[cited by applicant]
Geraghty et al., “Loss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment.” Neuron 103.2 (2019): 250-265.
[cited by applicant]
Gillepsie, A. et al., “Apolipoprotein E4 Causes Age-Dependent Disruption of Slow Gamma Oscillations during Hippocampal Sharp-Wave Ripples,” Neuron, vol. 90 (May 2016): 740-751.
[cited by applicant]
Gjoneska, E. et al., “Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease,” Nature, vol. 518 (Feb. 2015): 365-369.
[cited by applicant]
Gosselin, D. et al., “Environment drives selection and function of enhancers controlling tissue-specific macrophage identities,” Cell, vol. 159 (Dec. 2014): 1327-1340.
[cited by applicant]
Goutagny, R. et al., “Alterations in hippocampal network oscillations and theta-gamma coupling arise before Aβ overproduction in a mouse model of Alzheimer's disease,” European Journal of Neuroscience, vol. 37 (Jun. 201…
[cited by applicant]
Gray, C. et al., “Chattering cells: superficial pyramidal neurons contributing to the generation of synchronous oscillations in the visual cortex,” Science, vol. 274 (Oct. 1996): 109-113.
[cited by applicant]
Gray, C. et al., “Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties,” Nature, vol. 338 (Mar. 1989): 334-337.
[cited by applicant]
Harvey, C. et al., “Intracellular dynamics of hippocampal place cells during virtual navigation,” Nature, vol. 461 (Oct. 2009): 941-946.
[cited by applicant]
Helwig, M. et al., “The neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteins,” The Journal of Biological Chemistry, vol. 288 (Jan. 2013): 1114-1124.
[cited by applicant]
Hen Eka, M. et al., “Innate immune activation in neurodegenerative disease,” Nature Reviews Immunology, vol. 14 (Jul. 2014): 463-477.
[cited by applicant]
Hermann, C. et al., “Human EEG gamma oscillation in neuropsychiatric disorders,” Clinical Neurophysiology, vol. 116 (2005): 2719-2733.
[cited by applicant]
Hermann, C. et al., “Human EEG responses to 1-100 Hz flicker: resonance phenomena in visual cortex and their potential correlation to cognitive phenomena,” Experimental Brain Research, vol. 137 (Apr. 2001): 346-353.
[cited by applicant]
Gibson et al., “Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment.” Cell 176.1-2 (2019): 43-55.
[cited by applicant]
Hermelink, “Chemotherapy and cognitive function in breast cancer patients: the so-called chemo brain.” Journal of the National Cancer Institute Monographs 2015.51 (2015): 67-69.
[cited by applicant]
Hsiao, F. et al., “Altered Oscillation and Synchronization of Default-Mode Network Activity in Mild Alzheimer's Disease Compared to Mild Cognitive Impairment: an Electrophysiological Study,” PLOS One, vol. 8 (Jul. 2013)…
[cited by applicant]
Huang, S. et al., “Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages,” Nature Immunology, vol. 15 (Sep. 2014): 846-855,.
[cited by applicant]
Iliff, J. et al., “A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid B,” Science Trandlational Medicine, vol. 4 (Aug. 2012): 147.
[cited by applicant]
International Search Report and Written Opinion in International Patent Application No. PCT/US18/55258 dated Dec. 27, 2018. 16 pages.
[cited by applicant]
International Search Report and Written Opinion in International Patent Application No. PCT/US2018/051785 dated Jan. 24, 2019, 16 pages.
[cited by applicant]
International Search Report and Written Opinion issued by the International Searching Authority for Internaltional Application No. PCT/US16/63536, dated Mar. 27, 2017, 19 pages.
[cited by applicant]
International Search Report and Written Opinion issued by the International Searching Authority for International Application No. PCT/US16/63536, dated Mar. 27, 2017, 19 pages.
[cited by applicant]
Israel, M. et al., “Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells,” Nature, vol. 482 (Jan. 2012): 216-220.
[cited by applicant]
Japanese Office Action in Japanese Patent Application No. 2018-525754 dated Nov. 2, 2020, 13 pages.
[cited by applicant]
Jeong, J. “EEG dynamics in patients with Alzheimer's disease,” Clinical Neurophysiology, vol. 115 (Aug. 2004): 1490-1505.
[cited by applicant]
Khasabova et al., “Pioglitazone, a PPARγ agonist, reduces cisplatin-evoked neuropathic pain by protecting against oxidative stress.” Pain 160.3 (2019): 688-701.
[cited by applicant]
Koenig, T. et al., “Decreased EEG synchronization in Alzheimer's disease and mild cognitive impairment,” Neurobiology of Aging, vol. 26 (Feb. 2005): 165-171.
[cited by applicant]
Kreutzberg, G. “Microglia: a sensor for pathological events in the CNS,” Trends in Neurosciences, vol. 19 (Sep. 1996): 312-318.
[cited by applicant]
Kurudenkandy, F. et al., “Amyloid-β-Induced Action Potential Desynchronization and Degradation of Hippocampal Gamma Oscillations Is Prevented by Interference with Peptide Conformation Change and Aggregation,” The Journa…
[cited by applicant]
Laumet et al., “Cisplatin educates CD8+ T cells to prevent and resolve chemotherapy-induced peripheral neuropathy in mice.” Pain 160.6 (2019): 1459. 19 pages.
[cited by applicant]
Leinenga, G. et al., “Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model,” Science Translational Medicine, vol. 7 (Mar. 2015): 278.
[cited by applicant]
Leo et al., “Cisplatin-induced neuropathic pain is mediated by upregulation of N-type voltage-gated calcium channels in dorsal root ganglion neurons.” Experimental neurology 288 (2017): 62-74.
[cited by applicant]
Li, F. et al., “Effect of electroacupuncture stimulation of “Balhul” (GV 20) and “Yongquan” (KI 1) on expression of hippocampal amyloid-β and low density lipoprotein receptor-related protein-1 in APP/PS 1 transgenic mic…
[cited by applicant]
Lok, K. et al., “Characterization of the APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background,” Neuroscience Letters, vol. 557 (Dec. 2013): 84-89.
[cited by applicant]
Martorell et al., Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition. Cell. Mar. 14, 2019. https://dol.org/10.1016/j.cell.2019.02.014. 39 pages.
[cited by applicant]
Mastrangelo, M. et al., “Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice,” BMC Neuroscience, vol. 9 (Aug. 2008)…
[cited by applicant]
Meyers, “How chemotherapy damages the central nervous system.” Journal of biology 7.4 (2008): 11. 3 pages.
[cited by applicant]
Mind Alive Inc. http://mindalive.com/ Internet Archive Wayback Machine earliest Internet archived date Mar. 2, 2001, 2 pages.
[cited by applicant]
Mind Gear http://Mindlightz.com, Internet Archive Wayback Machine earliest Internet archived date Mar. 1, 2015, 5 pages.
[cited by applicant]
Mind Machines http://www.mindmachines.com/: Internet Archive Wayback Machine earliest Internet archived date Dec. 7, 1998, 4 pages.
[cited by applicant]
Mind Mods http://www.mindmods.com/, Internet Archive Wayback Machine earliest. Internet archived date Mar. 12, 2008, 2 pages.
[cited by applicant]
Mind Place http://mindplace.com/, Internet Archive Wayback Machine earliest Internet archived date Dec. 2, 1998, 4 pages.
[cited by applicant]
Mitrasinovic, O. et al., “Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Aβ,” Neurobiology of Aging, vol. 24 (Oct. 2003): 807-815.
[cited by applicant]
Neuro Alpha (Brain PBM). Vielight the Life Light 2019. Accessed at https://vielight.com/devices/vielight-neuro-alpha/ on Aug. 22, 2019. 7 pages.
[cited by applicant]
Neuronix http://neuronixmedical.com, Internet Archive Wayback Machine earliest Internet archived date Nov. 16, 2009, 2 pages.
[cited by applicant]
Neurotronics http://www.neurotronics.eu/, Internet Archive Wayback Machine earliest Internet archived date Sep. 24, 2008, 2 pages.
[cited by applicant]
Next Wave Physioacoustic MX therapy chair. Nextwave. Accessed at http://www.nextwaveworldwide.com/products/physioacoustic-mx-therapy-chair/ on Nov. 18, 2020. 2 pages.
[cited by applicant]
Notice of Allowance dated Apr. 25, 2018 for U.S. Appl. No. 15/647,157, 5 pages.
[cited by applicant]
Oakley, H. et al., “Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation,” Journal …
[cited by applicant]
O'Connor et al., “The use of the puzzle box as a means of assessing the efficacy of environmental enrichment.” JoVE (Journal of Visualized Experiments) 94 (2014): e52225. 8 pages.
[cited by applicant]
Ohmi, K. et al., “Defects in the medial entorhinal cortex and dentate gyrus in the mouse model of Sanfilippo syndrome type B,” Plos One, vol. 6 (Nov. 2011): 1-10.
[cited by applicant]
Palop, J. et al., “Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease,” Neuron, vol. 55 (Sep. 2007): 697-711.
[cited by applicant]
Paro Therapeutic Robot http://www.parorabots.com/: Internet Archive Wayback Machine earliest Internet Archived date Dec. 4, 2008, 2 pages.
[cited by applicant]